Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Journal: Expert opinion on investigational drugs
Published: May 29, 2024
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: September 09, 2022
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: April 19, 2016
Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
Journal: Annals of the rheumatic diseases
Published: January 15, 2013
Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?
Journal: Current rheumatology reports
Published: May 15, 2012
Showing 1-5 of 5
Last Updated: 09/26/2026